KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Resmed (RMD) Revenue (2016 - 2025)

Resmed's Revenue history spans 17 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Revenue rose 10.98% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $5.4 billion, up 9.57%, while the annual FY2025 figure was $5.1 billion, 9.84% up from the prior year.
  • Revenue reached $1.4 billion in Q4 2025 per RMD's latest filing, up from $1.3 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $1.4 billion in Q4 2025 to a low of $768.8 million in Q1 2021.
  • Average Revenue over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2023.
  • Peak YoY movement for Revenue: decreased 0.09% in 2021, then grew 29.2% in 2023.
  • A 5-year view of Revenue shows it stood at $894.9 million in 2021, then rose by 15.52% to $1.0 billion in 2022, then increased by 12.48% to $1.2 billion in 2023, then rose by 10.26% to $1.3 billion in 2024, then rose by 10.98% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for RMD's Revenue are $1.4 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.3 billion (Q2 2025).